Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform
Raanana, Israel -- Polyrizon Ltd., a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced compelling results from recent ex vivo studies demonstrating the mucoadhesive strength and extensive nasal surface coverage of its proprietary formulation platform.
The studies were conducted in collaboration with Prof. Fabio Sonvico's laboratory, utilizing excised rabbit nasal mucosa as a surrogate for human nasal tissues. The research aimed to characterize two key technological aspects of Polyrizon's formulation: surface coverage capability and mucoadhesive performance, both essential properties for protection against airborne biological assaults and for effective intranasal therapeutic delivery.
Advanced ex vivo studies using two-photon fluorescence microscopy demonstrated that Polyrizon’s formulation spreads rapidly and uniformly across the nasal mucosa, forming a consistent surface layer. The use of fluorescent markers confirmed that the formulation was accurately localized on the tissue, clearly distinguishable from natural tissue autofluorescence. This broad and uniform coverage is essential for ensuring effective localized protection or drug delivery. In parallel, mucoadhesion testing showed that the formulation maintains a strong and lasting attachment to the nasal tissue, even under conditions simulating physiological nasal fluid flow. This prolonged retention supports the potential for extended efficacy and enhances the potential for therapeutic benefit by helping the formulation stay in place long enough to exert its intended effect.
“These findings support our belief in our formulation’s ability to rapidly and effectively coat the nasal mucosa, a critical requirement for localized protection or delivery. This mucoadhesive profile is crucial for maintaining therapeutic efficacy in real-world conditions where mucociliary clearance can limit retention time " said Tomer Izraeli, CEO of Polyrizon.
Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T.
